Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUITION: Fruquintinib + TAS-102 vs Fruquintinib in Refractory Colorectal Cancer
NCT06992258Phase 2Recruiting
- Sponsor
- Criterium
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Criterium. Started Oct 2025; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06992258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992258.